CLLS

Rating neutralTentativeAI Memo

Cellectis

As of 2026-07-21/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-21 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

BALLI-01 pivotal Phase 2 interim analysis • 2026-10-31

Base target: $3 / p=50% prob

Biggest risk

The thesis remains dependent on binary clinical execution. Phase 1 results are not pivotal proof, analyst revision evidence is unavailable, and a disappointing Phase 2 readout or safety signal could drive a sharp reset.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

RMAT designation, encouraging early lasme-cel data, and a planned pivotal Phase 2 interim analysis provide a credible path to improved valuation if efficacy and safety hold. [#IR-2026-06-09] [#IR-2026-05-11]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-21

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

RMAT designation and EHA clinical update support near-term attention
NATHALI-01 full Phase 1 dataset
RMAT designation, encouraging early lasme-cel data, and a planned pivotal Phase 2 interim analysis provide a credible path to improved valuation if efficacy and safety hold.

BearKey bullets

Analyst target count, estimate revisions, and target-change evidence are unavailable.
Forward visibility is limited despite reported cash runway into Q4 2027.
[#IR-2026-05-11]

WatchKey bullets

BALLI-01 pivotal Phase 2 interim analysis

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=50%)

Target spread vs base: +79% / -50%

Scenario probabilities

Bull Target: $5 (p=20%)Base Target: $3 (p=50%)Bear Target: $1 (p=30%)

Commentary

Primary company news flow improved in June after the RMAT designation and EHA data release. The packet also contains a secondary report of a more than 24% after-hours rally, but no analyst revisions or social coverage are available; confidence therefore remains low and event-monitoring oriented.

As of 2026-07-21 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

RMAT designation and EHA clinical update support near-term attention
NATHALI-01 full Phase 1 dataset

Scenarios

Bull Target (Scenario probability)

$5 / p=20% prob

Base Target (Scenario probability)

$3 / p=50% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-07-21 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
BALLI-01 pivotal Phase 2 interim analysis
The first interim analysis of pivotal Phase 2 BALLI-01 is expected in Q4 2026. A supportive result could materially improve program credibility, while weak efficacy or safety could reset expectations. [#IR-2026-05-11]
Prob 54.00% • Move 30.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

RMAT designation and EHA clinical update support near-term attention
2026-07-31
Cellectis reported FDA RMAT designation for lasme-cel in relapsed/refractory B-ALL, followed by final Phase 1 BALLI-01 and preliminary eti-cel data at EHA 2026. The evidence improves regulatory and clinical visibility but remains early-stage. [#IR-2026-06-09] [#IR-2026-06-11]
Prob 67% • Move 12% • Priced-in 63%

Long-term Catalysts

Months to a year

NATHALI-01 full Phase 1 dataset
2026-12-31
Cellectis expects the full Phase 1 NATHALI-01 dataset for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma in Q4 2026. Positive data could broaden platform value, but this remains secondary to BALLI-01 and early clinical evidence. [#IR-2026-05-11] [#IR-2026-06-11]
Prob 46% • Move 18% • Priced-in 28%

Risks

Analyst target count, estimate revisions, and target-change evidence are unavailable.
Forward visibility is limited despite reported cash runway into Q4 2027. [#IR-2026-05-11]
NATHALI-01 remains earlier-stage and may not validate broader platform value.
Pivotal Phase 2 efficacy or safety may fail to confirm early BALLI-01 results.
Small-cap biotech event volatility creates substantial downside around clinical updates.

Peers

Symbol	Summary
NKTX	Closest packet comparator for development-stage cell-therapy catalyst volatility, but differing targets and programs limit clinical read-through.
VYGR	Small-cap gene-therapy risk comparator useful for framing partnering, runway, and event sensitivity rather than direct operating comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-21

Loading AI feed…

Symbol

Summary

NKTX

Closest packet comparator for development-stage cell-therapy catalyst volatility, but differing targets and programs limit clinical read-through.

VYGR

Small-cap gene-therapy risk comparator useful for framing partnering, runway, and event sensitivity rather than direct operating comparison.